Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, is heading into its most consequential period since flotation, as interim data from its lead drug candidate POLB 001 approaches and a second trial prepares to start.
POLB 001 is designed as an oral preventative therapy for cytokine release syndrome (CRS), a potentially life-threatening inflammatory reaction that affects more than 70% of patients receiving CAR T-cell and bispecific antibody cancer treatments.
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF, FRA:0C0) said Tuesday it has received registration approval from the Georgia Department of Agriculture for its mustard plant-based TerraSante organic biofertility product, expanding the company's commercial footprint in the southeastern US.
The Georgia organic certification falls under MustGrow's existing Organic OMRI Listed certifications, which also cover Florida, Arizona, Idaho, Oregon, and Washington State.
M2i Global Inc (OTC:MTWO) said on Tuesday that the one shareholder holding its Series A Super Voting Preferred Stock has voted in favor of the company's proposed merger with Volato Group, Inc. (NYSE American: SOAR), moving the deal a step closer to a final vote next month.
The preferred stockholder, whose shares carry 10,000 votes per share of voting stock, backed the transaction under which M2i Global will become a wholly owned subsidiary of Volato. Upon closing, Volato will be renamed M2i Global.
Alvopetro Energy Ltd (TSX-V:ALV, OTC:ALVOF, FRA:A6Y0) has won a final arbitration ruling that permanently secures its expanded working interest in Brazil's Caburé natural gas field, closing the door on a multi-year dispute with its joint venture partner.
The International Court of Arbitration of the International Chamber of Commerce ruled on April 27 that an independent expert's decision is "final, valid, and effective," definitively binding both parties under their Unit Operating Agreement.
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Michael A. Panzara as Chief Medical Officer, bringing aboard a veteran neurologist with more than 25 years of drug development experience as the biotechnology company braces for a critical clinical milestone in multiple sclerosis.
Panzara will oversee clinical development, medical affairs, and regulatory affairs at the Nasdaq-listed company, which is developing vidofludimus calcium, an oral therapy targeting both immunological and neuroprotective pathways in MS patients.
Premier African Minerals Ltd (AIM:PREM, OTC:PRMMF), the miner developing the Zulu Lithium and Tantalum Project in Zimbabwe, has raised £1 million through a share placing at 0.0136p each, as the company pushes to complete commissioning of a new processing plant in the second quarter.
The discount and dilution prompted 11% to 0.016p, having lost 96% of their value over the past year, leaving the company valued at just £3.4 million.
Panmure Liberum holds its 'buy' rating and 32p target as FDA fast-track status adds regulatory momentum to compelling trial data.
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) shares rose 5.3% to 13.69p on Tuesday as the cancer immunotherapy developer delivered a double dose of positive news.
Dimerix Ltd (ASX:DXB, OTC:SBMJF) has moved to strengthen the clinical and regulatory footing of its lead kidney disease program, confirming its pivotal ACTION3 trial remains on track with a high probability of success.
The update centres on a blinded statistical review of the Phase 3 study for DMX-200 in focal segmental glomerulosclerosis (FSGS), a rare and serious kidney disorder with limited treatment options.
Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5), the gene therapy developer, has signed additional confidentiality agreements with Tier-1 global animal health companies as interest grows in its canine ageing programme.
The agreements follow positive preliminary interim results from the company's dog study, announced in February, and build on an initial round of confidentiality agreements already in place.
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, is advancing partnering discussions with multiple pharmaceutical companies as it moves towards a series of near-term clinical data readouts that management believes could catalyse a deal.
Its lead programme, POLB 001, is being developed as a preventative therapy for Cytokine Release Syndrome (CRS), a potentially life-threatening immune overreaction triggered by certain cancer immunotherapies, particularly bispecific antibodies, which work by simultaneously binding to cancer cells and immune cells to direct an attack on tumours.
The AIM-listed biotech reports 77% progression-free survival at 20 months, well ahead of the standard of care
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the cancer immunotherapy developer, has secured a Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead drug candidate, iSCIB1+, in advanced melanoma.
St George Mining Ltd (ASX:SGQ, FRA:S0G, OTC:SGQMF) has delivered a standout March quarter, headlined by a major resource upgrade at its flagship Araxá rare earths and niobium project in Brazil, alongside growing momentum on downstream partnerships and development planning.
The company increased the Araxá Mineral Resource Estimate (MRE) by 75% to 70.91 million tonnes at 4.06% total rare earth oxides (TREO) and 0.62% niobium pentoxide (Nb₂O₅), reinforcing its position as a globally significant deposit.
European Lithium Ltd (ASX:EUR, OTCQB:EULIF) has unveiled a proposed merger with NASDAQ-listed Critical Metals Corp. (NASDAQ:CRML) that would see the two companies combine in an all-scrip deal valuing EUR at an implied A$0.58 per share — a significant premium to recent trading levels.
Under a non-binding indicative agreement, CRML would acquire 100% of European Lithium via a scheme of arrangement, with EUR shareholders receiving 0.035 CRML shares for each EUR share held.
Greatland Resources Ltd (AIM:GGP, OTC:GRLGF, FRA:G8G, ASX:GGP) has delivered March quarter gold production of 82,723 ounces alongside 4,128 tonnes of copper, with all-in sustaining costs (AISC) of $2,056 per ounce.
Year-to-date production for FY26 reached 249,887 ounces of gold and 11,022 tonnes of copper at an AISC of $2,136 per ounce, positioning the company to meet — or slightly exceed — the upper end of its 260,000–310,000 ounce full-year production guidance.
American Rare Earths Ltd (ASX:ARR, OTCQX:ARRNF) has bolstered its US-based leadership and technical bench as it moves to advance its flagship Halleck Creek rare earths project in Wyoming, appointing two senior figures focused on community engagement and project delivery.
The company has named Wyoming local Brook Brockman as director of public and government affairs for its subsidiary Wyoming Rare (USA) Inc., alongside Taylor Cable as director of projects and engineering, in a move aimed at strengthening both stakeholder relationships and execution capability.
AuMEGA Metals Ltd (ASX:AAM, TSX:AUM, OTCQB:AUMMF, FRA:FRA: MA30) has outlined a fully funded 2026 exploration program focused on resource growth, new discoveries and continued generation of drill-ready targets across its district-scale Cape Ray Shear Zone land package in Newfoundland, Canada.
The company’s work program will be built around three strategic initiatives:
Tamboran Resources Corporation (NYSE:TBN, ASX:TBN, OTC:TBNRL, FRA:O8R) plans to release its third-quarter earnings and operational update after the NYSE closes on Wednesday, May 13, 2026 (US time).
CEO Todd Abbott will host a webcast starting at 5:30pm EDT to provide an update on operations at the Beetaloo Basin, followed by a short Q&A session.
Elixir Energy Ltd (ASX:EXR, OTC:ELXPF) has started field operations for the stimulation, completion and flow testing of the Diona-1 well in the Surat-Bowen Basin in Queensland.
The company, operator and 49% holder of the ATP2077 Diona sub-block joint venture, said stimulation equipment had arrived at the well site and rigging up had started.
Resolution Minerals Ltd (ASX:RML, OTCQB:RLMLF, FRA:NC3) has produced high-grade tungsten concentrates of more than 52% tungsten trioxide (WO₃) from historical stockpiles at its Horse Heaven project in Idaho, delivering a strong upgrade from previously low-grade material.
Preliminary metallurgical test work delivered a 19-fold upgrade from the original stockpile grade of around 1.85% WO₃, using simple gravity separation techniques.
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has reported an 89.7% overall treatment success rate from its ongoing Remplir™ Real World Evidence study, supporting the company’s US commercial rollout and planned expansion into the EU and UK markets.
The latest data covers 66 patients and 78 nerve repair procedures, double the 33-patient cohort reported in September 2025.
Lindian Resources Ltd (ASX:LIN, OTC:LINIF) has updated investors on sulphuric acid supply arrangements for its SARECO mixed rare earth carbonate facility in Kazakhstan, following reports China will impose a near-total ban on sulphuric acid exports from May 1, potentially removing around 4.65 million tonnes of supply from global markets.
The SARECO facility sources sulphuric acid from the nearby Stepnogorsk Sulphuric Acid Plant (SSAP), a state-backed producer within Kazakhstan’s Samruk-Kazyna sovereign wealth fund.
Riversgold Ltd (ASX:RGL, FRA:RGV, OTC:RVSGF) has started geotechnical diamond drilling at its Northern Zone Gold Project, 25 kilometres east of Kalgoorlie in Western Australia, as it advances the project toward a Mine Development and Closure Plan (MDCP).
The short nine-day program is designed to collect the rock strength and structural data needed for open pit design, pit slope stability work and ongoing mine planning studies.